Recombinant Human Osteoprotegerin / TNFRSF11B Protein, His Tag, 100 µg

Background
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) is also known as Osteoclastogenesis inhibitory factor (OCIF), Osteoprotegerin (OPG). TNFRSF11B is a secreted homodimer protein, which can interact with TNFSF10 and TNFSF11. TNFRSF11B acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. TNFRSF11B inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.

Source
Recombinant Human Osteoprotegerin, His Tag (TNB-H5220) is expressed from human 293 cells (HEK293). It contains AA Glu 22 - Leu 401 (Accession # NP_002537). Predicted N-terminus: Glu 22

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 44.4 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "KLF4 haploinsufficiency in Sp7+ lineage leads to underdeveloped mandibles and insufficient elongation of mandibular incisor"
Guo, Yu, Zhang et al
Biochim Biophys Acta Mol Basis Dis (2022)
(2) "Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study"
Rob, Schierova, Stehlikova et al
PLoS One (2022) 17 (12), e0277576
(3)  "Nitric Oxide-Releasing Bioinspired Scaffold for Exquisite Regeneration of Osteoporotic Bone via Regulation of Homeostasis"
Lee, Kim, Park et al
Adv Sci (Weinh) (2022)
Showing 1-3 of 7842 papers.